Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial (vol 393, pg 1937, 2019)

Heerspink H. J. L.; Parving H-H; Andress D. L.

首页> 外文期刊>The Lancet >Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial (vol 393, pg 1937, 2019)

【24h】

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial (vol 393, pg 1937, 2019)

机译：患有2型糖尿病和慢性肾病（SONAR）患者的阿特拉森坦和肾脏事件：双盲，随机，安慰剂对照试验（第393 Vol 393，PG 1937,2019）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Lancet》 |2019年第10184期|共1页
作者
Heerspink H. J. L.; Parving H-H; Andress D. L.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献
专利

1. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial (vol 393, pg 1937, 2019) [J] . Heerspink H. J. L., Parving H-H, Andress D. L. The Lancet . 2019,第10184期

机译：患有2型糖尿病和慢性肾病（SONAR）患者的阿特拉森坦和肾脏事件：双盲，随机，安慰剂对照试验（第393 Vol 393，PG 1937,2019）
2. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial (vol 2, pg 369, 2014) [J] . Barnett A. H., Mithal A., Manassie J. The lancet. Diabetes & endocrinology. . 2015,第3期

机译：恩帕格列净与2型糖尿病和慢性肾脏病患者现有抗糖尿病治疗的有效性和安全性：一项随机，双盲，安慰剂对照试验（第2卷，第369页，2014年）
3. beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial (vol 393, pg 1597, 2019) [J] . Villanueva C., Albillos A., Genesca J. The Lancet . 2019,第10190期

机译：β受体阻滞剂，以防止在临床显着门诊高血压患者中的肝硬化的反作动力（预测）：随机，双盲，安慰剂控制，多期式试验（Vol 393，PG 1597,2019）
4. The Natural History of Chronic Kidney Disease Revisited-A 72-Month Mayo Health System Hypertension Clinic Practice-Based Research Network Prospective Report on End-Stage Renal Disease and Death Rates in 100 High-Risk Chronic Kidney Disease Patients: A Call for Circumspection [C] . Macaulay A.C. Onuigbo Conference on Peritoneal Dialysis . 2009

机译：慢性肾病的自然历史重新审议-A 72个月的MASO卫生系统高血压诊所的研究网络网络前期肾病和死亡率100个高危慢性肾病患者的死亡率：一个呼吁守则
5. The Use of Bayesian Principles to Predict the Optimal Revisit Interval and the Causal Relationship between Revisit Intervals and Chronic Kidney Disease for Medicare Patients with Type II Diabetes [D] . Lasway, Annie Enikunda. 2020

机译：贝叶斯原则的利用预测II型糖尿病患者Revisit间隔和慢性肾病的最佳Revisit区间和因果关系
6. Protocol: Effectiveness and acceptability of metformin in preventing the onset of type 2 diabetes after gestational diabetes in postnatal women: a protocol for a randomised placebo-controlled double-blind feasibility trial — Optimising health outcomes with Metformin to prevent diAbetes After pregnancy (OMAhA) [O] . Chiamaka Esther Amaefule, Angeliki Bolou, Zoe Drymoussi, 2020

机译：方案：二甲双胍预防产后妇女妊娠糖尿病后2型糖尿病发作的有效性和可接受性：一项随机安慰剂对照双盲可行性试验的方案-使用二甲双胍优化健康结局以预防妊娠后糖尿病（OMAhA ）
7. Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON) [O] . Dick de Zeeuw, Tadao Akizawa, Rajiv Agarwal, 2013

机译：慢性肾病患者百碱醇甲基评价的理由和试验设计及2型糖尿病：肾事件发生的发生（信标）

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial (vol 393, pg 1937, 2019)

著录项

相似文献

相关主题

期刊订阅